All Small Molecules articles – Page 2
-
NewsBlocking the P2X4 receptor: a potential pathway to new therapies
Researchers have discovered how to inhibit the P2X4 receptor, a key protein linked to chronic pain, inflammation and certain cancers.
-
NewsAI powers discovery of new CBLB inhibitor ISM3830
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
-
NewsKinase inhibitors shown to accelerate protein breakdown
A new study has revealed that many kinase inhibitors – key drugs used in cancer and other diseases – also trigger the accelerated degradation of their target proteins, which could inform future therapies.
-
ArticleMapping lipid pockets to drug the undruggable proteome
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
-
ArticleChemistry-aware AI offers new routes in small molecule design
AI has advanced molecule design, yet synthetic feasibility remains a bottleneck. Chemistry-first approaches offer a practical way forward.
-
ArticleInside Zasocitinib: a new model for TYK2 inhibition in immune-mediated diseases
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.
-
ArticleThe science behind the systematic discovery of molecular glues
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
-
NewsSoil’s hidden bacteria could hold future antibiotic breakthroughs
Researchers have unlocked the genetic secrets of soil’s hidden bacteria, discovering hundreds of previously unknown genomes and two promising new antibiotics.
-
ArticleInside the search-and-develop model tackling 1,000 untreated skin diseases
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
-
ArticleGene therapies that listen and respond: the power of RNA regulation
Most gene therapies rely on static DNA promoters to control gene activity, but nature uses far more sophisticated tools. Dr Matthew Dale explores how harnessing RNA-level control could enable treatments that sense and respond in real time, offering unprecedented precision and safety.
-
ArticleFrom injections to pills: oral peptides set to transform drug development
Oral peptide-based drugs are set to revolutionise the pharmaceutical industry, overcoming the long-standing challenge of poor bioavailability. Santosh Kulkarni reveals how new breakthroughs in drug discovery and delivery offer the potential for more convenient, effective treatments for a range of conditions – without the need for injections.
-
News
New class of chiral molecules offers strong stability for drug development
Scientists have created a new class of ultra-stable chiral molecules – a discovery that could lead to more precise drug design by preventing potentially harmful molecular “flipping” over time
-
NewsQTX153 reverses Rett symptoms and crosses key drug delivery barrier
QTX153, a novel HDAC6 inhibitor, has shown significant symptom reversal in preclinical models of Rett syndrome. This represents progress toward a therapy for a condition with no approved options.
-
NewsSmall molecule therapy improves islet transplant success in diabetes
A study from Weill Cornell Medicine shows that pre-treating pancreatic islet cells with a small molecule cocktail significantly improves survival after transplantation in type 1 diabetes models. The approach could help make donor cells go further and transplants more efficient.
-
NewsNew data backs Myo4 for obesity treatment
MitoRx Therapeutics has announced new preclinical data for its small molecule Myo4, showing restored insulin sensitivity and enhanced fat loss with muscle preservation in an obesity model - offering a potential alternative to GLP-1-based therapies.
-
ArticlePain relief without the risk: why SRP-001 could change everything
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
-
NewsAI targets protein linked to most human cancers
Scientists have used AI to design a molecule that disrupts a key protein interaction driving up to 70 percent of cancers - once thought impossible to drug.
-
ArticleWhat SLAS 2025 really told us about drug discovery
Forget the buzzwords - SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems.
-
NewsRare diseases, big advances: how research is powering a new era of treatments
This Friday, February 28, marks Rare Disease Day 2025, a global initiative raising awareness for the 300 million people living with rare conditions. Dr David Reynolds, CEO of LoQus23 Therapeutics, explores how advancements in rare disease research are driving the development of new treatments.
-
ArticleHow GPCR agonists, including antibodies, are shaping the future of metabolic care
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
- Previous Page
- Page1
- Page2
- Page3
- Next Page